JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S11

AI in Oncology: Enhancing Diagnostic Accuracy and Prediction with Machine Learning: A Systematic Review

Mohammed A Hassanien[1], Ayman Zaky Elsamanoudy[2], Sherif El Saadany[3], Basmah Eldakhakhny[4], Hamdy Tammam[5], Nezar Abo-Halawa[6], Rasha Ahmed Abou Kamer[7], Gehan A Hegazy[8], Mohab Sabry[9]*

1. Department of Pharmacy Practice and Assessment Unit, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
2. Clinical Biochemistry Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Mansoura University, Mansoura , Egypt.
3. Infectious diseases, Faculty of pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Egypt.
4. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
5. Orthopedic Department, Qena Faculty of Medicine, South Valley University, Egypt.
6. General Surgery Department Qena Faculty of Medicine, South Valley University, Egypt
7. Former lecturer at faculty of medicine , King Abdulaziz University Ministry of health , Egypt.
8. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Department of Medical Biochemistry, Medical Division, National Research Centre, Cairo, Egypt.
9. Cardiothoracic Surgery department, Faculty of Medicine, Tanta University, Egypt. King Abdulaziz Hospital, Ministry of Health, Jeddah, Saudi Arabia.

Email: mohab.sabry@med.tanta.edu.eg

ABSTRACT

Artificial intelligence (AI) has shown noteworthy potential in the diagnosis and management of malignant tumors. This systematic review summarizes the findings of several studies that investigated the application of AI in various aspects of Malignant Tumors management. The studies evaluated the performance of AI systems including machine learning and deep learning algorithms, in predicting resection outcomes in ovarian cancer, detecting malignant melanoma from histopathological sections, classifying skin cancer, and diagnosing melanoma. The results demonstrated that AI systems have comparable or superior performance compared to human experts in certain tasks, suggesting their potential to improve diagnostic accuracy and prediction. Patient attitudes towards AI in dermatology were generally positive with expectations of faster, more precise, and unbiased diagnostics. However, concerns about data protection, impersonality, and errors associated with AI need to be addressed. Integrating AI with human expertise has been shown to enhance the accuracy and reliability of skin cancer classification. AI-assisted CT imaging has demonstrated improved diagnostic accuracy and speed in pulmonary nodules, while the combination of AI with Raman spectroscopy has shown potential in breast cancer diagnosis. Continued collaboration between AI systems and healthcare professionals has the potential to revolutionize Malignant Tumors diagnosis and management, leading to improved patient outcomes and more efficient healthcare delivery.

KEYWORDS: Artificial intelligence (AI), diagnosis.

1. Introduction

AI has shown great potential for revolutionizing Malignant Tumors diagnosis and management. Through the integration of clinical, radiological, and histological data, AI tools can provide valuable information to improve investigative precision, tumor grades, treatment arrangement, and prognostic estimation (Liu et al., 2023). AI-assisted pathology recognition technology has the potential to enhance the efficiency and accuracy of pathologists, reducing the rate of misdiagnosis and missed diagnosis (Ferro et al., 2023). Moreover, AI plays a crucial role in prioritizing symptomatic individuals in the population whom at a heightened risk of emerging cancer in the future. (Huang et al., 2020). In hepatology field, AI utilized for diagnosing, treatment, and prognostic prediction of various disorders, showcasing its potential to enhance speed, accuracy, and reliability in cancer-related inquiries (Hunter et al., 2022).

Remarkable improvement has been achieved in the application of AI for the detection and treatment of lung cancer. Some studies demonstrate that AI outperforms traditional methods in terms of sensitivity and specificity for lung cancer diagnosis (Liu et al., 2023). AI can also predict the likelihood of malignancy in lung nodules, aiding in treatment decisions (Liu et al., 2023). Moreover, AI can analyze CT scans and identify early-stage lung cancer, leading to improved treatment outcomes (Liu et al., 2023).

Bladder cancer diagnosis and management can also benefit from AI. A comprehensive literature review reveals that AI can enhance the accuracy of bladder cancer diagnosis and reduce the need for invasive procedures (Ferro et al., 2023). AI can interpret the risk of recurrence and progression in bladder cancer, assisting clinicians in determining optimal treatment strategies (Elemento et al., 2021). Additionally, AI can analyze bladder cancer images and identify early-stage tumors and increase the likelihood of successful treatment (Ferro et al., 2023).

Gynecologic cancers can also be diagnosed and managed more effectively with AI. A systematic review highlights that AI improves the accuracy of gynecologic imaging and reduces the necessity for invasive procedures (Elemento et al., 2021). AI can predict the likelihood of malignancy in gynecologic tumors, aiding in treatment decision-making. Furthermore, AI can analyze gynecologic images and detect early-stage tumors, leading to better treatment outcomes (Huang et al., 2020). In the realm of skin cancer, AI has shown promising results in diagnosis and management. A contemporary review suggests that AI enhances the accuracy of skin cancer diagnosis and reduces the need for invasive procedures (Huang et al., 2020). AI can predict the likelihood of malignancy in skin lesions and guide treatment decisions (Huang et al., 2020). Additionally, AI can analyze skin cancer images and identify early-stage tumors improving treatment success rates (Elemento et al., 2021).

The purpose of the systematic review is to comprehensively evaluate and synthesize the existing literature on the application of AI in the diagnosis and management of malignant tumors. The purpose of the review is to give a comprehensive summary of the latest advancements in AI techniques, specifically ML and DL algorithms. These techniques are being used in different areas of tumor diagnosis and management, such as early detection, precise diagnosis, prediction of prognosis, planning of treatment, and assessment of response. Furthermore, the review aims to recognize the constraints, difficulties, and potential future paths in this rapidly developing f

2. Methodology

A. Search Strategy

An extensive search technique was utilized to locate pertinent studies on scholarly databases such as “PubMed”, “Web of Science”, and “Google Scholar”. The search was conducted from 2018 to 2023 to capture the most recent advances in the field of AI in the diagnosis and management of malignant tumors. The following keywords and their combinations were used in the search strategy: "artificial intelligence" "diagnosis" "management" "malignant tumors" "cancer" and related terms. After conducting the initial search, we obtained a total of 1421 studies. We then proceeded to the study selection process based on the defined inclusion and exclusion criteria. After filtration 12 studies met the criteria.

The inclusion criteria for study selection are:

- Studies published in peer-reviewed journals
- Studies focusing on the application of AI in the diagnosis and management of malignant tumors
- Studies reporting empirical findings
- Studies published in the English language

The exclusion criteria are:

- Non-peer-reviewed literature
- Studies not focusing on the application of AI in the diagnosis and management of malignant tumors
- Studies without empirical findings
- Studies published in languages other than English

C. Process of selecting studies

The study selection process encompassed several sequential stages in order to guarantee the incorporation of pertinent and high-caliber studies. At first, redundant research was eliminated utilizing reference management software. Subsequently, the titles and abstracts of the remaining articles were evaluated according to the predetermined criteria for inclusion. Following the initial screening, the whole texts of possibly eligible studies were obtained and subsequently evaluated for ultimate inclusion. The selection procedure was carried out autonomously by two reviewers, and any inconsistencies were resolved through discussion and agreement.

D. Data Extraction and Synthesis

Systematic data extraction was used to methodically gather pertinent information from the chosen studies. A standardized data extraction form was created, encompassing the following essential components: Examine the attributes of the study. (e.g., author, year of publication), aim and objectives, study design and methodology, key findings, and implications. The collected data were combined and examined to offer a thorough summary of the present advancements and potential prospects of AI in the identification and treatment of cancerous tumors. The synthesis involved a narrative synthesis approach which involved organizing and summarizing the findings from the included studies.

E. Quality Assessment:

The evaluation of the studies' quality was performed utilizing appropriate techniques, such as the “Newcastle-Ottawa Scale for observational studies” or the “Cochrane Risk of Bias tool” for randomized controlled trials. The quality assessment sought to appraise the methodological rigour and potential biases of the studies.

F. Interpretation of Findings:

The findings from the included studies were interpreted and discussed in the context of the research question. The strengths, limitations, and implications of the findings were considered, and potential areas for future research were identified.

G. Reporting:

The findings of the systematic review will be presented in accordance with the criteria set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The findings will be presented in a clear and organized way, which will include a flow diagram illustrating the process of selecting the studies, a summary of the key features of the studies that were included, and a narrative synthesis of the results.



Figure 1. Flow-chart of the article selection

3. Overview of AI in Malignant Tumors and Management

AI has become a potent tool in the medical industry, namely for the identification and treatment of cancerous tumors (Bi et al., 2019). AI comprises a range of strategies that empower computers to execute jobs that necessitate intelligence similar to that of humans. Machine Learning (ML) is a technology that employs algorithms with the ability to learn from data and provide predictions or judgements based on that data. ML algorithms can analyze extensive datasets of patient information in the context of malignant tumors to detect patterns and provide predictions about cancer diagnosis, prognosis, and treatment outcomes (Vicini et al., 2022).

DL is a subset of ML that leverages "artificial neural networks" to analyze complex data. DL algorithms excel in analyzing medical images such as CT scans and MRI scans, to detect tumors and other abnormalities. By detecting subtle changes in tissue on medical images, DL algorithms can aid in the early detection and diagnosis of cancer, enabling timely intervention and treatment (Koh et al., 2022). Natural Language Processing (NLP) is another AI technique that focuses on analyzing and understanding human language. In the context of malignant tumors, NLP algorithms can analyze medical records and other text-based data to identify patterns and make predictions regarding cancer diagnosis and treatment. By extracting relevant information from textual sources, NLP algorithms contribute to more accurate and efficient decision-making in cancer management (El Naqa et al., 2020).

AI is essential in identifying and diagnosing malignant tumors at an early stage. ML algorithms has the capacity to analyze medical imagery in order to detect tumors and anomalies that human radiologists may overlook. (Zhou et al., 2020). This enhances the accuracy of diagnosis and increases the chances of early intervention, leading to better patient outcomes (Rudie et al., 2019). DL algorithms, with their ability to detect subtle changes in tissue are particularly valuable in identifying early-stage tumors (Chua et al., 2021). Moreover, AI plays an important role in treatment planning and the field of personalized medicine. Machine learning algorithms have the capability to examine patient data, which encompasses genetic information and medical history, in order to choose the most optimal treatments for particular patients (Huynh et al., 2020). This enables the development of personalized treatment approaches tailored to the distinctive characteristics of each patient., hence enhancing the effectiveness of treatment and reducing the occurrence of negative side effects. Deep learning algorithms can enhance treatment planning by analyzing medical images to ascertain the most advantageous surgical strategy for tumor extraction. (Koh et al., 2022).

Prognosis and prediction of treatment outcomes are important aspects of cancer management, and AI-based tools can aid in these areas as well. Machine learning algorithms have the capability to analyze patient data in order to determine the characteristics that have an impact on treatment outcomes, such as age, gender, and medical history. (Luchini et al., 2022). By considering various patient-specific factors, ML algorithms can provide insights into treatment success and guide decision-making processes. DL algorithms can predict the likelihood of tumor recurrence by analyzing medical images and identifying subtle indicators of disease progression. NLP algorithms can also contribute to prognosis by analyzing medical records and other text-based data, providing valuable information regarding treatment success and patient outcomes (Farina et al., 2022).

4. Review of Studies

Laios et al. (2020) assessed the efficiency of an AI system, specifically the “k-nearest neighbor” (k-NN) classifier, in predicting the successful removal of macroscopic disease (R0 resection) Among patients diagnosed with Stage IV ovarian, tubal, and primary peritoneal tumours who were receiving surgical cytoreduction. There were 154 participants in the study, all of whom had terminal, high-grade serous ovarian, tubal, or primary peritoneal cancer. Multiple variables, including age, BMI, Charlson Comorbidity Index, scheduling of surgery, surgical difficulty, and disease score, were taken into account. The “k-NN” algorithm was used to classify patients as R0 or non-R0 based on 3-20 nearest neighbors. The study found that the k-NN algorithm showed promising results in predicting R0 resection. Its accuracy is anticipated to increase with additional data, and it marginally surpassed logistic regression. The results indicate that AI systems, such as the k-NN classifier, have the potential to surpass traditional predictive algorithms in their effectiveness for routine clinical use in the management of ovarian cancer.

Wang et al. (2020) created a sophisticated AI system known as a DLS that has the ability to autonomously identify malignant melanoma (MM) in the eyelid using histological sections. A retrospective analysis was carried out of 225,230 pathological patches extracted from 155 whole-slide images (WSI) stained with hematoxylin and eosin (H&E). A “convolutional neural network” (CNN) was utilized to develop a deep learning model for the purpose of classifying patches as either cancerous or benign. Subsequently, the model was employed to produce a graphical representation of a heatmap and determine a diagnostic at the whole slide image (WSI) level using a random forest model. The DLS demonstrated exceptional precision, sensitivity, and specificity in identifying MM at the patch level. Furthermore, it effectively delineated the affected region on whole slide images (WSIs) through the utilization of a probabilistic heatmap. The study showcases the capacity of AI, particularly deep learning, to automate the identification of malignant melanoma from histological slides. This advancement has the potential to assist in the timely detection and treatment of the disease.

In their study, Hekler et al. (2019) explored the potential advantages of integrating human expertise with AI in the classification of skin cancer. The study included a dataset consisting of 11,444 dermoscopic pictures, which were categorized into five distinct diagnostic groups. An image classification model was built using a DL approach which relies on CNNs. A novel classifier was developed by integrating the diagnoses given by dermatologists with the trained CNN through a gradient boosting technique. The study revealed that the integration of human expertise and AI yielded higher outcomes in the classification of skin cancer, surpassing the individual performance of each system. When comparing the accuracy, sensitivity, and specificity of the individual classifiers to the aggregate classifier, the latter performed better. The results indicate that combining AI with human experience can improve the precision and dependability of skin cancer diagnosis.

Brinker et al. (2019) assessed the efficacy of a CNN, a type of AI system, in accurately categorizing photos of” melanoma and nevi”. The CNN's performance was then compared to that of dermatologists' classifications. CNN was trained using a dataset of 4,204 biopsy-proven pictures of “melanoma and nevi”. A panel of dermatologists from nine German university hospitals assessed an additional 804 dermoscopic images and offered their recommended course of treatment. McNemar's tests were performed to assess the sensitivity, specificity, and overall accuracy of the CNN and dermatologists' results. The CNN, after being trained, demonstrated markedly superior specificity and sensitivity in “lesion classification” as compared to dermatologists. The study showed the advantage of AI-based automated dermoscopic melanoma picture categorization over both junior and board-certified dermatologists. The results indicate that AI systems such as convolutional neural networks (CNNs) have the potential to enhance accuracy and aid in the early diagnosis of melanoma.

Winkler et al. (2020) examined how well a convolutional neural network (CNN) can accurately diagnose melanoma in various locations and subtypes. The study used a CNN, specifically the Moleanalyzer-Pro®, for classifying malignant and benign lesions in dermoscopic images. Six image sets representing different melanoma localizations and subtypes were included. The performance of the CNN was assessed in terms of specificity and sensitivity and receiver operating characteristics-area under the curve (ROC-AUC). The CNN demonstrated excellent diagnostic accuracy in the majority of picture sets, surpassing certain thresholds for sensitivities, specificities, and ROC-AUC values. However, CNN's performance was limited in mucosallesions and subtypes with low prevalence. The study highlights the potential of CNNs in melanoma diagnosis but also emphasizes the need for further research and improvements in handling specific subtypes and challenging cases.

Jutzi et al. (2020) conducted a study in Germany to assess the perspectives of patients, specifically those with earlier history of melanoma, about the use of AI in melanoma diagnoses. 94% of participants expressed their approval for the utilization of AI in medical methodologies, while 88% indicated their willingness to offer their health data for the advancement of AI-driven apps. Just 41% of participants expressed willingness to embrace AI as a standalone system, however an overwhelming 94% showed support for its utilization as an auxiliary system for doctors. Patients expressed apprehensions over data security, lack of human touch, and potential for inaccuracies, while anticipating AI to deliver expedited, accurate, and impartial diagnostic outcomes.

Nelson et al., 2020, Conducted qualitative interviews with patients to explore their conceptualization of AI and their perceptions of AI for skin cancer screening. Patients primarily conceptualized AI in terms of cognition. Perceived benefits of AI included increased diagnostic speed and improved healthcare access, while increased patient anxiety was seen as a potential risk. Patients emphasized synergy between artificial intelligence and humans in healthcare decision-making. 75% of patients would recommend AI to family and friends for skin cancer screening.

Research by Maron and colleagues in 2020 Explored the possibility that dermatologists' ability to differentiate between melanoma and nevi might be enhanced with the help of AI. Using and without a trained CNN, dermatologists categorized dermoscopy images of nevi and melanomas. While dermatologists' mean specificity stayed the same, their mean sensitivity and accuracy improved dramatically with AI support. When the CNN agreed with the patient, their confidence in the decision grew, but when it disagreed, it fell. The findings lend credence to the idea that dermatologists can benefit from AI-powered systems that classify skin lesions.

In 2022, Han and colleagues Using a randomized controlled trial, we tested the hypothesis that AI could improve the skin cancer diagnostic accuracy of average doctors in clinical practice. There was a statistically significant difference in accuracy between the groups who used AI and those that did not. The difference was more noticeable for residents in dermatology than for trainees in fields other than dermatology. Trainees were able to incorporate more differential diagnoses with the aid of the AI system. The accuracy of the AI algorithm's top predictions decreased, though, when they were wrong.

Felmingham et al., 2022, Described a pre-intervention/post-intervention study evaluating the use of an AI algorithm for lesion assessment in dermatology clinics. A dermoscopy camera captured images of lesions, which were then categorized as benign, malignant, or unsure by an AI system. Analyzed was the AI algorithm's effect on management and diagnostic choices. By comparing the AI algorithm's classifications with those of dermatologists and histopathologists, we were able to assess its safety and accuracy.

In their work, Du et al. (2022) evaluated the diagnostic effectiveness of AI-assisted CT imaging in differentiating between benign and malignant lung nodules. The study involved gathering CT scan screening data on lung nodules from November 2018 to November 2020. The study group consisted of 152 individuals, all of whom had clear pathology results, with a total of 194 nodules found. The study employed a methodology that involved comparing diagnostic outcomes obtained from AI, human physician readings, multidisciplinary team (MDT) diagnoses, and postoperative pathology data.

Performance indicators such as accuracy, specificity, sensitivity, positive predictive value, negative predictive value, false negative rate, and false positive rate were calculated for each diagnostic procedure. ROC curves were constructed to visually represent the diagnostic capabilities of the various techniques. The results revealed that AI achieved an precision rate of 89.69%, a sensitivity rate of 92.98%, a specificity rate of 65.22%, and a Youden index of 58.20%. In addition, the diagnostic results obtained from the analysis of physician reading and MDT evaluation were carefully examined. The MDT demonstrated superior performance in terms of accuracy, sensitivity, specificity, and the Youden index. Ultimately, the study suggested that introducing an AI system for detecting pulmonary nodules has the potential to improve the accuracy and reliability of early lung cancer diagnosis. In addition, the system was discovered to decrease the average time it takes to detect something, thereby providing physicians with more accurate information to guide their clinical decision-making.

In their study, Talari et al. (2019) investigated the integration of AI and ML with Raman spectroscopy (RS) to achieve precise medical diagnosis and decision-making. The study aimed to examine breast cancer tissues by employing Raman spectroscopy (RS) and chemometric techniques. An analysis was conducted on breast biopsies using tissue microarray. Both supervised and unsupervised algorithms were utilized to examine the biochemical alterations linked to various subtypes of breast cancer. The study determined that the integration of RS with AI and ML has the possible to offer a meticulous and exact approach for cancer diagnosis and surveillance.

5. Synthesis of Findings

The studies primarily concentrate on the use of machine learning and deep learning algorithms, including k-nearest neighbor classifiers, convolutional neural networks (CNNs), and gradient boosting approaches. These AI systems demonstrate promising results in various aspects of cancer diagnosis including predicting resection outcomes, detecting melanoma from histopathological slides, and classifying skin cancer types (Han et al., 2022; Nelson et al., 2020; Jutzi et al., 2020; Winkler et al. 2020; Brinker et al. 2019; Maron et al., 2020). The performance of AI systems often shows comparable or superior accuracy when compared to human experts. However, the studies also highlight the need for further research and improvements, particularly in handling specific subtypes, challenging cases, and ethical implementation.

The reviewed studies have several strengths that contribute to the understanding of AI in tumor diagnosis and management. They employ rigorous methodologies including large sample sizes, diverse patient populations, and comprehensive data analysis (Felmingham et al., 2022, Talari et al.,2019). The studies also use “state-of-the-art AI” algorithms and techniques, as k-NN classifiers, CNNs, and deep learning models, which enhance the accuracy and performance of the systems. Moreover, some studies incorporate qualitative interviews and surveys to capture patients' perspectives and attitudes towards AI in cancer diagnostics (Han et al., 2022; Nelson et al., 2020; Jutzi et al., 2020; Winkler et al. 2020; Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019; Wang et al. (2020),.

However, certain limitations should be acknowledged. The studies predominantly rely on retrospective data analysis, which may introduce selection biases and limit the generalizability of the findings. The performance of AI systems vary depending on the specific dataset and population characteristics. Furthermore, the studies often focus on specific tumor types or subtypes which may restrict the broader applicability of the findings. Additionally, the ethical considerations of implementing AI systems in clinical practice including data protection, impersonality, and potential errors, need to be carefully addressed (Felmingham et al., 2022, Talari et al.,2019).

B. Strengths and limitations of the studies

The studies reviewed employ rigorous study designs including retrospective reviews, randomized controlled trials, and surveys. The use of large datasets and diverse populations enhances the generalizability of the findings. The application of state-of-the-art AI techniques such as k-NN, CNNs, and deep learning, demonstrates the potential of these methods in improving diagnostic accuracy and prediction. Additionally, the studies consider various outcome measures including accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and false positive/negative rates, providing comprehensive insights into the performance of AI systems (Han et al., 2022; Nelson et al., 2020; Jutzi et al., 2020; Winkler et al. 2020; Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019; Wang et al. (2020),

Despite these strengths, the studies also have some limitations. The sample sizes in some studies may be relatively small, limiting the generalizability of the findings. The retrospective nature of some studies may introduce selection bias. The reliance on specific datasets and image sets may impact the external validity of the results. Additionally, the studies primarily focus on specific tumor types such as ovarian cancer and melanoma, which may limit the generalizability of the findings to other tumor types. Furthermore, the studies do not extensively explore the ethical considerations and implementation challenges associated with the integration of AI systems in clinical practice (Felmingham et al., 2022, Talari et al.,2019).

The use of AI systems such as k-NN classifiers, CNNs, and deep learning models, shows promise in improving diagnostic accuracy and prediction in the diagnosis and treatment of cancer. These AI systems have the potential to outperform conventional predictive algorithms and even human experts in certain tasks. Clinicians can benefit from incorporating AI as an assistance system for decision-making, as it can enhance diagnostic performance. The combination of human expertise with AI algorithms has been shown to achieve superior results in skin cancer classification and melanoma diagnosis. This suggests that AI can serve as a valuable tool to support and augment the capabilities of clinicians (Nelson et al., 2020; Jutzi et al., 2020; Winkler et al. 2020; Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019).

6. Discussion

The findings of the reviewed studies highlight the potential of AI systems in improving the diagnosis and management of malignant tumors. The use of ML algorithms, such as k-NN, logistic regression, and CNNs, has shown promising results in various applications. These AI systems have demonstrated their potential in predicting resection outcomes in ovarian cancer, detecting malignant melanoma from histopathological slides, and classifying skin cancer lesions. The combination of human expertise with AI algorithms has been found to enhance diagnostic accuracy and reliability. Integrating the diagnoses made by dermatologists with AI algorithms using gradient boosting or CNNs has shown improved performance in skin cancer classification and melanoma diagnosis. The combined classifier outperformed the individual classifiers in terms of accuracy, sensitivity, and specificity (Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019).

The studies also indicate that AI systems can provide improved accuracy compared to human experts in certain tasks. AI systems, namely CNNs, demonstrated superior sensitivity and specificity in classifying lesions compared to dermatologists. This indicates that AI systems have the potential to aid in the early detection of tumors. AI systems have shown promise in various medical domains, including radiology, pathology, and dermatology (Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019). Previous studies have demonstrated the potential of AI in improving diagnostic accuracy and prediction in various diseases, including cancer (Hunter et al., 2022; Ferro et al., 2023; Elemento et al., 2021).

In the field of dermatology, AI systems have been developed to classify and diagnose skin lesions, including melanoma. Research has demonstrated that AI algorithms can attain a high level of precision in differentiating between harmless and cancerous skin lesions, frequently matching or surpassing the abilities of human dermatologists. These findings align with the results of the reviewed studies, which also highlight the superiority of AI systems in skin cancer classification (Han et al., 2022; Nelson et al., 2020; Jutzi et al., 2020; Winkler et al. 2020; Brinker et al. 2019; Maron et al., 2020; Hekler et al. 2019; Wang et al. 2020). Similarly, in the field of pathology, AI has been applied to histopathological slides for the detection and diagnosis of cancer. AI algorithms have shown promise in accurately identifying cancerous cells and predicting tumor behavior. The reviewed studies that focused on the analysis of histopathological slides for melanoma diagnosis align with this existing literature (Felmingham et al., 2022, Talari et al.,2019). In radiology, AI has been used to assist in the detection and characterization of tumors in various organs such as the lungs, breast, and brain. AI algorithms have demonstrated the ability to detect subtle abnormalities and assist radiologists in making accurate diagnoses. While the reviewed studies did not specifically focus on radiological imaging, the findings regarding the potential benefits of AI in improving diagnostic accuracy align with the existing literature in radiology (Laios et al., 2020; Du et al.,2022; Felmingham et al., 2022, Talari et al.,2019).

C. Limitations and future directions

Despite the promising findings, there are several limitations and challenges that need to be addressed in future research. One limitation is the lack of standardized datasets and evaluation metrics of studies. This makes it difficult to directly compare the performance of different AI systems and to generalize the findings. Future research should aim to establish standardized datasets and evaluation protocols to facilitate better comparison and benchmarking of AI algorithms. Another limitation is the potential bias in the training data used to develop AI systems. If the training data is biased or lacks diversity, the AI system may inherit and perpetuate those biases, leading to disparities in diagnosis and treatment. It is crucial to ensure that AI systems are trained on diverse and representative datasets to minimize bias and ensure equitable healthcare outcomes.

Furthermore, the implementation of AI systems in clinical practice raises ethical considerations and challenges. Issues such as patient privacy, explainability of AI algorithms, and the appropriate role of AI as an assistant to human clinicians need to be carefully addressed. Future research should explore these ethical considerations and develop guidelines and frameworks for the responsible integration of AI in the clinical practice. Long-term studies are also needed to assess the impact of AI on patient outcomes, healthcare costs, and workflow efficiency. It is essential to evaluate whether the use of AI systems leads to improved patient outcomes and more efficient healthcare delivery. Additionally, cost-effectiveness analyses should be conducted to determine the economic feasibility and sustainability of implementing AI systems in clinical practice.

7. Conclusion

Review of studies on AI in the diagnosis and management of cancer highlights the potential benefits of AI systems in improving diagnostic accuracy and prediction. ML algorithms such as k-NN, logistic regression, and CNNs have shown promise in various applications including predicting resection outcomes, detecting melanoma, and classifying skin lesions. Combining human expertise with AI algorithms has been found to enhance diagnostic accuracy and reliability while AI systems have shown comparable or superior performance compared to human experts in certain tasks. The integration of AI as an assistance system in clinical practice has the potential to improve diagnostic speed, increase healthcare access, and provide more precise and unbiased diagnostics.

References

Liu, M., Wu, J., Wang, N., Zhang, X., Bai, Y., Guo, J., Zhang, L., Liu, S., & Tao, K. (2023). The value of artificial intelligence in the diagnosis of lung cancer: A systematic review and meta-analysis. PloS one, 18(3), e0273445.

Ferro, M., Falagario, U. G., Barone, B., Maggi, M., Crocetto, F., Busetto, G. M., Giudice, F. D., Terracciano, D., Lucarelli, G., Lasorsa, F., Catellani, M., Brescia, A., Mistretta, F. A., Luzzago, S., Piccinelli, M. L., Vartolomei, M. D., Jereczek-Fossa, B. A., Musi, G., Montanari, E., Cobelli, O., … Tataru, O. S. (2023). Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. Diagnostics (Basel, Switzerland), 13(13), 2308.

Hunter, B., Hindocha, S., & Lee, R. W. (2022). The role of artificial intelligence in early cancer diagnosis. Cancers, 14(6), 1524.

Elemento, O., Leslie, C., Lundin, J., & Tourassi, G. (2021). Artificial intelligence in cancer research, diagnosis and therapy. Nature Reviews Cancer, 21(12), 747-752.

Huang, S., Yang, J., Fong, S., & Zhao, Q. (2020). Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer letters, 471, 61-71.

Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., ... & Aerts, H. J. (2019). Artificial intelligence in cancer imaging: clinical challenges and applications. CA: a cancer journal for clinicians, 69(2), 127-157.

Zhou, J., Zeng, Z. Y., & Li, L. (2020). Progress of artificial intelligence in gynecological malignant tumors. Cancer Management and Research, 12823-12840.

Chua, I. S., Gaziel-Yablowitz, M., Korach, Z. T., Kehl, K. L., Levitan, N. A., Arriaga, Y. E., ... & Hassett, M. (2021). Artificial intelligence in oncology: Path to implementation. Cancer Medicine, 10(12), 4138-4149.

Koh, D. M., Papanikolaou, N., Bick, U., Illing, R., Kahn Jr, C. E., Kalpathi-Cramer, J., ... & Prior, F. (2022). Artificial intelligence and machine learning in cancer imaging. Communications Medicine, 2(1), 133.

Vicini, S., Bortolotto, C., Rengo, M., Ballerini, D., Bellini, D., Carbone, I., ... & Faggioni, L. (2022). A narrative review on current imaging applications of artificial intelligence and radiomics in oncology: Focus on the three most common cancers. La radiologia medica, 127(8), 819-836.

Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022). Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nature Reviews Clinical Oncology, 19(2), 132-146.

Rudie, J. D., Rauschecker, A. M., Bryan, R. N., Davatzikos, C., & Mohan, S. (2019). Emerging applications of artificial intelligence in neuro-oncology. Radiology, 290(3), 607-618.

El Naqa, I., Haider, M. A., Giger, M. L., & Ten Haken, R. K. (2020). Artificial Intelligence: reshaping the practice of radiological sciences in the 21st century. The British journal of radiology, 93(1106), 20190855.

Huynh, E., Hosny, A., Guthier, C., Bitterman, D. S., Petit, S. F., Haas-Kogan, D. A., ... & Mak, R. H. (2020). Artificial intelligence in radiation oncology. Nature Reviews Clinical Oncology, 17(12), 771-781.

Luchini, C., Pea, A., & Scarpa, A. (2022). Artificial intelligence in oncology: current applications and future perspectives. British Journal of Cancer, 126(1), 4-9.

Farina, E., Nabhen, J. J., Dacoregio, M. I., Batalini, F., & Moraes, F. Y. (2022). An overview of artificial intelligence in oncology. Future Science OA, 8(4), FSO787.

Talari, A. C., Rehman, S., & Rehman, I. U. (2019). Advancing cancer diagnostics with artificial intelligence and spectroscopy: identifying chemical changes associated with breast cancer. Expert review of molecular diagnostics, 19(10), 929-940.

Laios, A., Gryparis, A., DeJong, D., Hutson, R., Theophilou, G., & Leach, C. (2020). Predicting complete cytoreduction for advanced ovarian cancer patients using nearest-neighbor models. Journal of Ovarian Research, 13, 1-8.

Wang, L., Ding, L., Liu, Z., Sun, L., Chen, L., Jia, R., ... & Ye, J. (2020). Automated identification of malignancy in whole-slide pathological images: identification of eyelid malignant melanoma in gigapixel pathological slides using deep learning. British Journal of Ophthalmology, 104(3), 318-323.

Hekler, A., Utikal, J. S., Enk, A. H., Hauschild, A., Weichenthal, M., Maron, R. C., ... & Thiem, A. (2019). Superior skin cancer classification by the combination of human and artificial intelligence. European Journal of Cancer, 120, 114-121.

Brinker, T. J., Hekler, A., Enk, A. H., Berking, C., Haferkamp, S., Hauschild, A., ... & Utikal, J. S. (2019). Deep neural networks are superior to dermatologists in melanoma image classification. European Journal of Cancer, 119, 11-17.

Brinker, T. J., Hekler, A., Hauschild, A., Berking, C., Schilling, B., Enk, A. H., ... & Utikal, J. S. (2019). Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. European Journal of Cancer, 111, 30-37.

Winkler, J. K., Sies, K., Fink, C., Toberer, F., Enk, A., Deinlein, T., ... & Haenssle, H. A. (2020). Melanoma recognition by a deep learning convolutional neural network—performance in different melanoma subtypes and localisations. European Journal of Cancer, 127, 21-29.

Hekler, A., Utikal, J. S., Enk, A. H., Berking, C., Klode, J., Schadendorf, D., ... & Brinker, T. J. (2019). Pathologist-level classification of histopathological melanoma images with deep neural networks. European Journal of Cancer, 115, 79-83.

Jutzi, T. B., Krieghoff-Henning, E. I., Holland-Letz, T., Utikal, J. S., Hauschild, A., Schadendorf, D., ... & Brinker, T. J. (2020). Artificial intelligence in skin cancer diagnostics: the patients' perspective. Frontiers in medicine, 7, 233.

Nelson, C. A., Pérez-Chada, L. M., Creadore, A., Li, S. J., Lo, K., Manjaly, P., ... & Mostaghimi, A. (2020). Patient perspectives on the use of artificial intelligence for skin cancer screening: a qualitative study. JAMA dermatology, 156(5), 501-512.

Maron, R. C., Utikal, J. S., Hekler, A., Hauschild, A., Sattler, E., Sondermann, W., ... & Brinker, T. J. (2020). Artificial intelligence and its effect on dermatologists' accuracy in dermoscopic melanoma image classification: web-based survey study. Journal of medical Internet research, 22(9), e18091.

Han, S. S., Kim, Y. J., Moon, I. J., Jung, J. M., Lee, M. Y., Lee, W. J., ... & Chang, S. E. (2022). Evaluation of Artificial Intelligence–Assisted Diagnosis of Skin Neoplasms: A Single-Center, Paralleled, Unmasked, Randomized Controlled Trial. Journal of Investigative Dermatology, 142(9), 2353-2362.

Han, S. S., Moon, I. J., Kim, S. H., Na, J. I., Kim, M. S., Park, G. H., ... & Chang, S. E. (2020). Assessment of deep neural networks for the diagnosis of benign and malignant skin neoplasms in comparison with dermatologists: A retrospective validation study. PLoS medicine, 17(11), e1003381.

Felmingham, C., MacNamara, S., Cranwell, W., Williams, N., Wada, M., Adler, N. R., ... & Mar, V. (2022). Improving Skin cancer Management with ARTificial Intelligence (SMARTI): protocol for a preintervention/postintervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a specialist dermatology setting. BMJ open, 12(1), e050203.

Du, W., He, B., Luo, X., & Chen, M. (2022). Diagnostic value of artificial intelligence based on CT image in benign and malignant pulmonary nodules. Journal of Oncology, 2022.